Profession Physician | Name Charles Sawyers | |
 | ||
Full Name Charles Lazelle Sawyers Born 1959 (age 55–56) Nashville, Tennessee Education Johns Hopkins University Institutions Memorial Sloan-Kettering Cancer Center
Howard Hughes Medical Institute Research Leukemia/Prostate Cancer Notable prizes Lasker Clinical Award (2009)
BBVA Foundation Frontiers of Knowledge Award (2014) | ||
Charles sawyers 2014 breakthrough prize in life sciences symposium
Charles L. Sawyers is a Howard Hughes Medical Institute (HHMI) investigator who holds the Marie-Josée and Henry R. Kravis Chair of the Human Oncology and Pathogenesis Program (HOPP) at Memorial Sloan Kettering Cancer Center (MSK). HOPP is a program created in 2006 that comprises researchers from many disciplines to bridge clinical and laboratory discoveries.
Contents
- Charles sawyers 2014 breakthrough prize in life sciences symposium
- Interview with charles sawyers
- Career
- Significant positions
- Memberships
- Awards
- References
Interview with charles sawyers
Career
Sawyers received a BA from Princeton University in 1981 and an MD from Johns Hopkins University School of Medicine in 1985, followed by an internal medicine residency at the University of California, San Francisco. He became a HHMI investigator in 2002 while at working at UCLA's Jonsson Cancer Center.
Sawyers works on molecularly targeted cancer drugs, with a focus on developing a new generation of treatment options for patients. He shared the 2009 Lasker-DeBakey Clinical Medical Research Award with Brian J. Druker and Nicholas Lydon, for the development of the ABL kinase inhibitor imatinib for patients with chronic myeloid leukemia and the second generation ABL inhibitor dasatinib to overcome imatinib resistance. He also co-discovered the antiandrogen drug enzalutamide that was approved by the FDA in 2012 for treatment of advanced prostate cancer.
Significant positions
Sawyers served as President of the American Society of Clinical Investigation (ASCI) in 2007 and of the American Association for Cancer Research (AACR) in 2012. He was also appointed to the National Cancer Advisory Board by President Obama in 2012, and has served on the Board of Directors of Novartis since 2013.
Memberships
Awards
